MOUNTAIN VIEW, Calif. (AP) — Drug developer Vivus Inc. said Thursday the Food and Drug Administration will make a decision in its impotence drug candidate avanafil by April 29, 2012.
Vivus said the FDA accepted the application for marketing approval that it filed on June 30. It owns the worldwide rights to avanafil except in some Asian Pacific Rim countries.
Shares of Vivus fell 34 cents, or 4.1 percent, to $8 on Thursday. The stock declined 9 cents to $7.91 in after-hours trading.